Results 181 to 190 of about 18,044 (238)

The Switch from Reference Biologic Medicines to Biosimilars in France: The Perspective of Patients and Prescribers on Barriers and Needs. [PDF]

J Multidiscip Healthc
Gaujoux-Viala C, Tropé S, Buisson A, Lacombe F, Bocquet F, Languérand E, Cordurié L, Margulies G, Le Berre C, Vittecoq O.   +9 more
europepmc   +1 more source

Innovative approach to support therapeutic proteins' similarity in hydrodynamic size using high-throughput dynamic light scattering and forced degradation. [PDF]

Sci Rep
Bhirde A, Harish S, Trunfio N, de Luna IF, Smith W, Fu Q.   +5 more
europepmc   +1 more source

Regulierung und adäquate Preisbildung im Markt der Biosimilars: Projekt im Auftrag der Pfizer Deutschland GmbH

, 2017
Altin, Sibel, Bauer, Cosima, May, Uwe, Walendzik, Anke, Wasem, Jürgen, Ziebe, Anissa   +5 more
core  

Comparative outcomes of aflibercept biosimilars and reference aflibercept in nAMD: a systematic review and meta-analysis. [PDF]

BMJ Open Ophthalmol
Sawires K, Nithianandan H, Somani S.
europepmc   +1 more source

HASH(0x563d440b87b0) [PDF]

, 2007
Groth, S.
core  

Comparative Safety Analysis of Avastin and Bevacizumab Biosimilars Based on Food and Drug Administration Adverse Event Reporting System. [PDF]

Basic Clin Pharmacol Toxicol
Zhang X, Zhang Y, Tang X, Chen L.
europepmc   +1 more source

Knowledge, Attitudes, and Practices Regarding Biosimilars Among Pharmacists and Physicians in Saudi Arabia: A Scoping Review. [PDF]

Cureus
Alanizi A, Alotaibi R, Babalghaith R, Alzahrani A, Qubaiban R, Hattan A, Alnuhait M, Al Sharif A.   +7 more
europepmc   +1 more source

Past, present and future of nivolumab: new horizons in immuno-oncology. [PDF]

Front Oncol
Madar IH, Kammarambath SR.
europepmc   +1 more source

Short-term outcomes of aflibercept biosimilar SB15 in macular edema secondary to retinal vein occlusion. [PDF]

BMC Ophthalmol
Cho J, Park SM, Kim CG, Kim JH.
europepmc   +1 more source

​Did a Non-Medical Biosimilar Switching Policy Cause an Increase in Non-Biologic/Biosimilar Health Care Resource Utilization or Cost in Patients With Inflammatory Arthritis? [PDF]

Arthritis Care Res (Hoboken)
Dang H, Blitz S, Bansback N, Law M, Harrison M.   +4 more
europepmc   +1 more source